



Harrow Health to Announce Fourth Quarter and Year-End 2021 Financial Results on March 10, 2022

February 24, 2022

NASHVILLE, Tenn.--(BUSINESS WIRE)--Feb. 24, 2022-- Harrow Health, Inc. (NASDAQ: HROW), an ophthalmic-focused healthcare company, today announced that it will release its financial results for the fourth quarter and year ended December 31, 2021, on Thursday, March 10, 2022, after the market close. The Company will also post its fourth quarter Letter to Stockholders to the "Investors" section of its website, harrowinc.com. Harrow Health will host a conference call and live webcast at 4:45 p.m. Eastern Time to discuss the results and provide a business update.

Conference Call Details:

Date:	Thursday, March 10, 2022
Time:	4:45 p.m. Eastern time
Participant Dial-in:	1-833-953-2434 (U.S.) 1-412-317-5763 (International)
Replay Dial-in (Passcode 6231870): <i>(telephonic replay through March 17, 2022)</i>	1-877-344-7529 (U.S.) 1-412-317-0088 (International)
Webcast: (online replay through June 10, 2022)	harrowinc.com

About Harrow Health

Harrow Health, Inc. (NASDAQ: HROW) is an ophthalmic-focused healthcare company. The Company owns and operates [ImprimisRx](#), one of the nation's leading ophthalmology-focused pharmaceutical businesses, and [Visionology](#), a direct-to-consumer eye care subsidiary focused on chronic vision care. Harrow Health also holds non-controlling equity positions in [Eton Pharmaceuticals](#), [Surface Ophthalmics](#) and [Melt Pharmaceuticals](#), all of which started as Harrow Health subsidiaries, and owns royalty rights in four clinical-stage drug candidates being developed by Surface Ophthalmics and Melt Pharmaceuticals. For more information about Harrow Health, please visit the Investors section of the corporate website, harrowinc.com.

View source version on [businesswire.com](https://www.businesswire.com/news/home/20220224005223/en/): <https://www.businesswire.com/news/home/20220224005223/en/>

Jamie Webb, Director of Communications and Investor Relations
jwebb@harrowinc.com
615-733-4737

Source: Harrow Health, Inc.